Department of Neurosurgery
Greifswald, 17475, Germany
NCT Number: NCT02887417
Glioblastoma face an increased risk of venous or arterial thromboembolism. Furthermore, the most frequent immune cells in glioblastoma are tumor associated macrophages, which find theirself in an anti-inflammatory (M2) phenotype.
Increased conjugates between circulating platelets and monocytes reflect an pro-inflammatory status.
Looking for future studies?
Notify Me18 year–100 year
All sexes
Observational
Greifswald, 17475, Germany
Glioblastoma face an increased risk of venous or arterial thromboembolism. Furthermore, the most frequent immune cells in glioblastoma are tumor associated macrophages, which find theirself in an anti-inflammatory (M2) phenotype.
Increased conjugates between circulating platelets and monocytes reflect an pro-inflammatory status.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 01/ 2016 - 10/ 2016
Time frame: 01/ 2016 - 10/ 2016
Time frame: 01/ 2016 - 10/ 2016
Time frame: 01/ 2016 - 10/ 2016
University Medicine Greifswald
Other
Acronym: GPAS
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03739372
Astrocytoma, Cancer
San Diego, California, United States
View Trial DetailsNCT02761070
Astrocytoma, Disease Attributes
Nagoya, Aichi-ken, Japan
View Trial DetailsNCT04730869
Astrocytoma, Behavior
Hamilton, Waikato Region, New Zealand
View Trial DetailsNCT01339052
Astrocytoma, Brain Diseases
Los Angeles, California, United States
View Trial Details